<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225251</url>
  </required_header>
  <id_info>
    <org_study_id>gsk 102149</org_study_id>
    <nct_id>NCT00225251</nct_id>
  </id_info>
  <brief_title>Wellbutrin XL for Dysthymic Disorder</brief_title>
  <official_title>Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic
      disorder, a form of low-grade chronic depression. We hypothesize that patients taking
      Wellbutrin XL will show greater improvement in depression symptoms and psychosocial
      functioning than patients taking placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a ten-week, double-blind, placebo-controlled study designed to evaluate the
      tolerability, dosing and efficacy of Wellbutrin XL in outpatients who meet Diagnostic and
      Statistical Manual-IV criteria for early onset, primary type dysthymic disorder (low-grade
      chronic depression). It is hypothesized that patients taking Wellbutrin XL will show greater
      improvement in depression symptoms and psychosocial functioning than patients taking placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale, 24 Items (HDRS)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Widely used depression rating scale, with higher scores reflecting greater level of depression. Assesses suicidality which is a safety issue.
This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cornell Dysthymia Rating Scale (CDRS)</measure>
    <time_frame>10 weeks</time_frame>
    <description>A 24 item scale assessing symptoms of chronic depression. Scores from 0 to 96 with higher score indicating worse depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>10 weeks</time_frame>
    <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Improvement (CGI)</measure>
    <time_frame>10 weeks</time_frame>
    <description>A global assessment of patient improvement, ranging from 1 (very much improved) to 7 (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Functioning Scale (GAFS)</measure>
    <time_frame>10 weeks</time_frame>
    <description>A clinician rated assessment of patient's overall functioning, ranging from 0 (severely impaired) to 100 (excellent functioning)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Dysthymic Disorder</condition>
  <arm_group>
    <arm_group_label>bupropion XL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion XL</intervention_name>
    <description>Antidepressant medication</description>
    <arm_group_label>bupropion XL</arm_group_label>
    <other_name>Wellbutrin XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients 18-65 years of age.

          -  Patients with a Diagnostic and Statistical Manual Fourth Edition (DSM-IV) diagnosis of
             dysthymic disorder, early onset.

          -  Patients will have a total score of 12 or higher on the Hamilton Depression Scale (24
             items) at baseline.

        Exclusion Criteria:

          -  Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other
             Cognitive Disorders.

          -  Patients who are pregnant or nursing women.

          -  Patients with a principal diagnosis meeting DSM-IV criteria for: Major Depressive
             disorder, Bipolar Disorder or cyclothymia, Schizophrenia, Delusional (Paranoid)
             Disorders and Psychotic Disorders not elsewhere classified, Severe Borderline
             Personality Disorder

          -  Patients who have a current or prior diagnosis of Anorexia Nervosa or Bulimia

          -  Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence
             on any drug, including alcohol.

          -  Patients who would pose a serious risk for suicide during the course of the study, as
             evidenced by one of the following:

               -  Report of having a specific plan for killing themselves,

               -  A score of 3 or higher on the Hamilton Depression Rating Scale item #3 as rated
                  by the treating clinician at Week 0, (indicative of active suicidal thoughts or
                  behaviors), or

               -  A suicide attempt within the past 12 months requiring emergency room visit,
                  medical or psychiatric hospitalization, or otherwise deemed to be
                  life-threatening (e.g. an overdose of &gt; 1 week's dose of medication).

          -  Patients with a history of recurrent Grand Mal seizures or at risk of Grand Mal
             seizures, and those with other medical conditions in which Wellbutrin XL would be
             contraindicated, including a history of head trauma.

          -  Use of any psychotropic medication within 1 week of starting study medication

          -  Use of a monoamine oxidase inhibitor (a type of antidepressant) (MAOI) within the 14
             days prior to the initial dose of study medication.

          -  Use of fluoxetine within 28 days of the initial dose of study medication.

          -  Use of ZybanÂ® or other forms of bupropion hydrochloride (i.e. Wellbutrin immediate
             release or Wellbutrin Sustained Release (SR)) within 2 weeks of the initial dose of
             medication.

          -  Patients who have failed to respond to adequate trials (minimum of six consecutive
             weeks) of two different classes of antidepressant medication (see Table 1 for
             definitions of an adequate trial.)

          -  Patients with unstable medical conditions, such as acute hyperthyroidism, uncorrected
             hypothyroidism, undiagnosed fever, uncontrolled angina, or any other serious medical
             illness, including any cardiovascular, hepatic, respiratory, hematological,
             endocrinologic or neurologic disease, or any clinically significant laboratory
             abnormality.

          -  Patients who have begun a course of psychotherapy within 3 months of starting the
             study, or who plan to terminate an ongoing psychotherapy prior to the end of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center, and NY State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.DepressionNY.com</url>
    <description>For more information about our program or this study, click here.</description>
  </link>
  <reference>
    <citation>Hellerstein DJ, Batchelder S, Kreditor D, Fedak M. Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol. 2001 Jun;21(3):325-9.</citation>
    <PMID>11386496</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <results_first_submitted>May 13, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysthymic Disorder</keyword>
  <keyword>Dysthymia</keyword>
  <keyword>Depression</keyword>
  <keyword>Chronic Depression</keyword>
  <keyword>Wellbutrin XL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion XL</title>
          <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>adults with dysthymic disorder, males and females</population>
      <group_list>
        <group group_id="B1">
          <title>Bupropion XL</title>
          <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="11.5"/>
                    <measurement group_id="B2" value="40.0" spread="10.9"/>
                    <measurement group_id="B3" value="40.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale, 24 Items (HDRS)</title>
        <description>Widely used depression rating scale, with higher scores reflecting greater level of depression. Assesses suicidality which is a safety issue.
This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale, 24 Items (HDRS)</title>
          <description>Widely used depression rating scale, with higher scores reflecting greater level of depression. Assesses suicidality which is a safety issue.
This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="6.9"/>
                    <measurement group_id="O2" value="13.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.0</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cornell Dysthymia Rating Scale (CDRS)</title>
        <description>A 24 item scale assessing symptoms of chronic depression. Scores from 0 to 96 with higher score indicating worse depression</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Cornell Dysthymia Rating Scale (CDRS)</title>
          <description>A 24 item scale assessing symptoms of chronic depression. Scores from 0 to 96 with higher score indicating worse depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="10.8"/>
                    <measurement group_id="O2" value="24" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="4.4"/>
                    <measurement group_id="O2" value="12.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Improvement (CGI)</title>
        <description>A global assessment of patient improvement, ranging from 1 (very much improved) to 7 (very much worse)</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Improvement (CGI)</title>
          <description>A global assessment of patient improvement, ranging from 1 (very much improved) to 7 (very much worse)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1"/>
                    <measurement group_id="O2" value="2.43" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Functioning Scale (GAFS)</title>
        <description>A clinician rated assessment of patient's overall functioning, ranging from 0 (severely impaired) to 100 (excellent functioning)</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Functioning Scale (GAFS)</title>
          <description>A clinician rated assessment of patient's overall functioning, ranging from 0 (severely impaired) to 100 (excellent functioning)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="8.6"/>
                    <measurement group_id="O2" value="67" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <desc>patients were assessed for side effects over the course of the efficacy study</desc>
      <group_list>
        <group group_id="E1">
          <title>Bupropion XL</title>
          <description>Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
bupropion XL: Antidepressant medication</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>patient reported dry mouth</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>patient reported headache</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <description>patient reported dizziness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>reported difficulty sleeping</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination led to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hellerstein MD</name_or_title>
      <organization>NY State Psychiatric Institute</organization>
      <phone>6467748000</phone>
      <email>hellers@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

